Patient preferences for psoriasis treatments: Process characteristics can outweigh outcome attributes

Archives of Dermatology

Volumn 147, Issue 11, 2011, Pages 1285-1294

  Schaarschmidt, Marthe Lisa ^b   Schmieder, Astrid ^a   Umar, Nasir ^b   Terris, Darcey ^b,c   Goebeler, Matthias ^a,d   Goerdt, Sergj ^a   Peitsch, Wiebke K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GEORGIA   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CONJOINT ANALYSIS; DEMOGRAPHY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EMPLOYMENT STATUS; FEMALE; GERMANY; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; SCORING SYSTEM; SOCIOECONOMICS; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DECISION MAKING; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PSORIASIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SOFTWARE; YOUNG ADULT;

EID: 81855190660     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.309     Document Type: Article

References (43)

1. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-J321.
2. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52(3, pt 1):434-444.
3. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139. (Pubitemid 38457271)
4. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(2)(suppl):S57-S61. (Pubitemid 36951248)
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284. (Pubitemid 32240779)
6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. (Pubitemid 351509656)
7. Menter A, Korman NJ, Elmets CA, et al.; American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 3: guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 5: guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114-135.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 4: guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
10. Nast A, Boehncke WH, Mrowietz U, et al. S3-Guidelines for the treatment of psoriasis vulgaris Update 2011 [in German]. J Dtsch Dermatol Ges. 2011;9(suppl 2):S1-S104. doi:10.1111/j.1610-0379.2011.07680.x.
11. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1-70.
12. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3, pt 1):401-407. (Pubitemid 29418506)
13. Gokdemir G, Ari S, Köşlü A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22(3):330-335. (Pubitemid 351247423)
14. Dubertret L, Mrowietz U, Ranki A, et al.; EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729-736. (Pubitemid 44352553)
15. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol. 2002;138(3):337-342. (Pubitemid 34226331)
16. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-414. (Pubitemid 38469243)
17. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581-583. (Pubitemid 29480408)
18. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20(4):370-379.
19. Ross CK, Steward CA, Sinacore JM. The importance of patient preferences in the measurement of health care satisfaction. Med Care. 1993;31(12):1138-1149.
20. Zug KA, Littenberg B, Baughman RD, et al. Assessing the preferences of patients with psoriasis: a quantitative, utility approach. Arch Dermatol. 1995;131(5):561-568.
21. Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2008;158(2):351-359.
22. Delfino M Jr, Holt EW, Taylor CR, Wittenberg E, Qureshi AA. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol. 2008;59(3):439-447.
23. Opmeer BC, Heydendael VM, deBorgie CA, et al. Patients with moderate-tosevere plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol. 2007;60(7):696-703. (Pubitemid 46891754)
24. Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis. 2010;69(2):352-357.
25. Kjaer T, Bech M, Gyrd-Hansen D, Hart-Hansen K. Ordering effect and price sensitivity in discrete choice experiments: need we worry? Health Econ. 2006;15(11):1217-1228. (Pubitemid 44696949)
26. Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with UK dermatologists. Br J Dermatol. 2006;155(6):1236-1241. (Pubitemid 44730001)
27. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143(9):1175-1179. (Pubitemid 47443371)
28. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530-1533. (Pubitemid 30330316)
29. Claes C, Kulp W, Greiner W, Graf von der Schulenberg J, Werfel T. Therapie der mittelschweren und schweren Psoriasis. In: Deutsche Agentur für Health Technology Assessment des Dutschen Instituts für Medizinische Dokumentation und Information. Vol 34. Köln, Germany: German Institute for Medical Documentation and Information; 2006:15-46, 91-94.
30. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(suppl 2):10-16.
31. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. (Pubitemid 44205029)
32. Green P, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Mark. 1990;54(4):3-19.
33. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. (Pubitemid 24194579)
34. Backhaus K, Erichson B, Plinke W, Weiber R, eds. Multivariate Analysemethoden. Vol 11. Berlin, Germany: Springer; 2006.
35. Hahn M, Schulz T. Health economic aspects of psoriasis therapy: is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints? Hautarzt. 2005;56(6):576-580. (Pubitemid 40933247)
36. Sminkels OQ, Prins M, Veeniiuis RT, et al. Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol. 2004;14(3):159-165. (Pubitemid 38738455)
37. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: metaanalysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513-526.
38. Jones-Caballero M, Unaeze J, Peñas PF, Stern RS. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol. 2007;143(7):846-850. (Pubitemid 47076481)
39. Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol. 2009;160(6):1340-1343.
40. Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146(6):1006-1016. (Pubitemid 34779481)
41. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140-147. (Pubitemid 38457272)
42. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075-1082.
43. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45(1):72-76. (Pubitemid 32655696)